What does “Imatinib ever greening” mean?
“Evergreening” is a term used for strategies where a company tries to extend a drug’s market exclusivity beyond what the original patent would allow, often by filing new patents around small changes (like new formulations, new dosing regimens, or new uses) or by adjusting the product in ways that qualify for additional legal protection. Whether something counts as “evergreening” depends on the jurisdiction and the specific patents or regulatory exclusivity that were granted or challenged.
Has imatinib been linked to evergreening disputes?
Yes. Imatinib (marketed as Gleevec) has been the subject of long-running debate and litigation in multiple places about whether certain patenting and exclusivity moves around the drug were intended to extend monopoly protection rather than reflect a genuinely new therapeutic advance. These disputes are often discussed in connection with how patent thickets and follow-on filings can affect when generic or biosimilar competitors enter the market.
What kinds of follow-on filings can be considered “evergreening” for imatinib?
Common mechanisms that are criticized in “evergreening” arguments include:
- Patents on new formulations or delivery approaches (even if the active ingredient is the same).
- Patents on new dosing schedules or treatment durations.
- Patents tied to new indications or patient subgroups.
- Requests for regulatory exclusivity extensions that can delay generic entry.
The exact categorization for imatinib depends on which specific follow-on patents or exclusivity grants were issued and how they were interpreted or challenged.
How do evergreening claims affect generic entry for imatinib?
If evergreening-related patents are upheld or regulatory exclusivities are granted, generic companies may face delays because they cannot launch “at risk” or may need to wait for patent expiry. Conversely, if courts or regulators narrow or invalidate follow-on claims, generics can enter sooner.
Where you may be seeing this term online
People often use “imatinib evergreening” in posts or articles about:
- Patent litigation around Gleevec and generic competition timing.
- Patent “evergreening” in oncology more broadly (imatinib is a frequent example because it was widely used and has a long patent and generics timeline).
Quick clarification so I can answer precisely
Which country or context do you mean (for example, India, the UK/EU, the US), and are you asking about:
1) specific imatinib patent cases, or
2) whether imatinib generics entered later than expected due to follow-on filings?
If you tell me the jurisdiction or link what you saw, I can map the claim to the specific patents/exclusivity involved.
Sources
No sources were provided in your prompt, so I can’t cite specific cases or filings yet.